PALO ALTO, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that its Board of Directors has approved changing the previously announced record date of January 28, 2025 for its previously announced dividend of Scilex preferred stock (the “Dividend”) to its stockholders and certain other securityholders of Scilex. The new record date for the Dividend will be April 11, 2025 (the “New Record Date”). Subject to the Board’s right to further change the New Record Date, the payment date (the “Payment Date”) will be determined by subsequent resolutions of the Board, which will be within 60 days following the New Record Date.

Read more here:
Scilex Holding Company Announces Change in Record Date for its Previously Announced Dividend of Preferred Stock Exchangeable for up to 10% of...

SUNNYVALE, Calif., March 10, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the Japan Patent Office has granted Japanese Patent No. 7641330 titled “Radial and Transendocardial Delivery Catheter” with a patent term that will expire on or after September 30, 2034.

See original here:
BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System

TORONTO, March 10, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its LaNeo™ MDMA), is excited to announce that it has signed a distribution agreement with Duchefa Farma B.V. (“Duchefa”) of Haarlem, Netherlands, to act as exclusive distribution agent for its LaNeo MDMA in the Netherlands market.

Continue reading here:
PharmAla Signs Duchefa Farma as Exclusive Distributor in Netherlands

Please read the announcement in PDF

See the rest here:
Transactions under Novonesis’ share buyback program

Company Announcement

See the original post here:
Genmab Announces Johnson & Johnson Decision Regarding HexaBody®-CD38

MESQUITE, NV, March 10, 2025 (GLOBE NEWSWIRE) -- March 10, 2025 – Mesquite, NV – Dogecoin Cash, Inc. ($CBDS), a publicly traded leader in blockchain innovation, is excited to announce its strategic expansion into the rapidly growing meme coin market. Inspired by the meteoric success of recent meme coins launched by high-profile figures like Donald Trump and Melania Trump, $CBDS is forming a new subsidiary, MEME COINS Inc., to drive acquisitions and investments in the space while protecting shareholder equity.Riding the Wave of Cultural RelevanceMeme coins have become a powerful cultural and financial force, with billions of dollars traded daily. Their unique blend of viral marketing, community-driven support, and speculative appeal has attracted both retail and institutional investors. The success of high-profile meme coins underscores the immense potential for innovation in this space.“As we’ve seen with recent launches, meme coins have evolved into a mainstream asset class, engaging investors in ways traditional cryptocurrencies have not. Through the formation of MEME COINS Inc. we are structuring our expansion to maximize opportunities while minimizing dilution for CBDS shareholders,” said David Tobias, CEO of Dogecoin Cash, Inc.Why the Meme Coin Market?The exponential growth of the meme coin market is driven by:Global Appeal – Meme coins transcend borders and demographics, fueled by internet culture. Community Power – Strong online communities drive engagement and long-term value. New Revenue Streams– Meme coins can integrate into broader ecosystems, creating opportunities for DeFi, NFTs, and gaming. Cultural Influence – Endorsements from public figures and brands amplify adoption and legitimacy. CBDS and MEME COINS Inc. will build a diversified portfolio of meme coin assets and projects that combine cultural relevance with sound financial utility.Formation of MEME COINS Inc. and Strategic Acquisition PlanTo execute this vision while avoiding dilution to $CBDS shareholders, the company is launching a wholly owned subsidiary, MEME COINS Inc., which will focus on:Acquiring Established Meme Coins – Targeting assets like Dogecoin and other high-potential meme coins. Issuing Preferred Shares – MEME COINS Inc. will raise funds through preferred shares rather than issuing common stock, ensuring that CBDS shareholders maintain their equity positions. Strategic Partnerships & Investments – Investing in new and existing meme coin projects with strong community engagement and financial potential. This approach allows $CBDS to capitalize on the meme coin boom while preserving its equity structure and protecting long-term investor value.The $CBDS Business PlanDogecoin Cash, Inc. and MEME COINS Inc. will execute a three-pronged strategy:1. Development of Proprietary Meme Coins – Launching branded meme coins with real-world applications, such as charity contributions, gamification, and exclusive content access. 2. Partnerships with Influencers – Collaborating with cultural icons and internet influencers to drive viral marketing campaigns. 3. Community-First Ecosystem – Creating a platform where meme coin communities can trade, engage, and participate in decentralized governance. Commitment to Sustainable GrowthDogecoin Cash, Inc. is uniquely positioned to add legitimacy and long-term value to the meme coin market by emphasizing transparency, security, and scalability. Through responsible development, strategic acquisitions, and financial innovation, the company aims to redefine how meme coins are perceived and utilized.Looking AheadDogecoin Cash, Inc. invites investors, developers, and the broader cryptocurrency community to join us in this bold venture. Through MEME COINS Inc., we are not only embracing the future of digital finance but also ensuring that our investors benefit from this explosive market with minimal dilution.For more information about Dogecoin Cash, Inc. and MEME COINS Inc. visit www.cbds.com.

Link:
Dogecoin Cash, Inc. ($CBDS) Expands into Meme Coin Market with Formation of MEME COINS Inc.

Psyence Group settles Debt for Shares Psyence Group settles Debt for Shares

Continued here:
Psyence Group's NASDAQ-Listed Associate, Psyence Biomedical, names Albert P. Garcia-Romeu, Ph.D. as Chair of its Newly Created Scientific Advisory...

WARREN, N.J., March 10, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech company, today announced the filing of a new patent with the U.S. Patent and Trademark Office (USPTO) for its under-development T cell vaccine. Unlike many vaccines that primarily induce a B cell response, Tevogen Bio’s design aims to leverage the Company’s proprietary Tevogen.AI-powered PredicTcell technology to identify peptides which stimulate a T cell response.

Read this article:
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO

Press Release

Here is the original post:
MSInsight Announces €1.6 Million in Seed Fundraising to Revolutionize MSI Cancer Diagnosis

ORION CORPORATION STOCK EXCHANGE RELEASE – CHANGES IN COMPANY’S OWN SHARES10 MARCH 2025 at 19.00 EET

Go here to read the rest:
Orion Corporation: Transfer of 191,911 own B shares on 10 March 2025

Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

More here:
Immunocore presents initial multiple ascending dose data for HIV functional cure candidate in an oral presentation at CROI 2025

NEWTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in webcast fireside chats at two upcoming investor conferences:

Read this article:
Acumen Pharmaceuticals to Participate in Upcoming Investor Conferences

Dosing Initiated in Cohort 2 of the MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic Cardiomyopathy

Visit link:
Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

A new batch of neflamapimod capsules led to increased plasma drug concentrations and demonstrated improvement (p<0.001 vs. old capsules; p=0.003 vs. placebo) on the primary outcome measure, change from baseline in Clinical Dementia Rating Sum of Boxes (CDR-SB)

Read more here:
CervoMed Announces Positive Results from the Extension Phase of its Phase 2b Clinical Study of Neflamapimod in Patients with Dementia with Lewy Bodies

– Annual net revenue increased 4% to $267.0 million in 2024, despite significant divestitures –– UDENYCA® net revenue increased 62% year-over-year –– LOQTORZI® net revenue increased 29% quarter-over-quarter –

Read the original:
Coherus BioSciences Reports Fourth Quarter, Full Year 2024 Financial Results and Provides Business Update

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), March 10, 2025 - GENFIT (Nasdaq and Euronext: GNFT), a biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases (the “Company”), today announces the results of the bondholders’ vote at the general meeting of the 2025 OCEANEs holders which took place this Monday, March 10, 2025 at 2:30pm (Paris time): all resolutions proposed by the Company were approved.

More here:
Royalty Financing with HCRx: GENFIT Announces Approval of the Amendment of the Terms and Conditions of its 2025 OCEANEs

TUSCALOOSA, Ala., March 10, 2025 (GLOBE NEWSWIRE) -- Druid City Vital Care (“Druid City”) was recently recognized at the Vital Care Infusion Services annual conference in Orlando, FL.   Three locations -- Tuscaloosa, AL, Tupelo, MS, and North Augusta, SC -- each received Top Gun awards for performance. The Memphis location won the Fast Starter award for the most revenue in their first year. Tuscaloosa was recognized as the #1 franchise in the Vital Care franchisee network for 2023 and 2024, and achieved the milestone of being the first Vital Care site to ever exceed $100 million in receipts for a calendar year.

Originally posted here:
Druid City Vital Care Recognized at Vital Care Infusion Services Annual Conference

WOBURN, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Abpro Holdings, Inc. (Nasdaq:ABP) ("Abpro"), a biotechnology company dedicated to advancing next-generation antibody therapies for severe and life-threatening diseases announced today the departure of Chief Executive Officer Ian Chan.

Original post:
Abpro Statement on the Departure of Former CEO Ian Chan

STOUGHTON, Mass., March 10, 2025 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have two poster presentations highlighting real-world data from its differentiated neuropsychiatry product, Jornay PM, (methylphenidate HCl), a central nervous system (CNS) stimulant for the treatment of attention deficit hyperactivity disorder (ADHD) at the National Association of Pediatric Nurse Practitioners (NAPNAP) 46th National Conference on Pediatric Health Care, being held in Chicago, IL, from March 10-13, 2025.

Link:
Collegium Announces Poster Presentations at the 2025 National Association of Pediatric Nurse Practitioners National Conference on Pediatric Health...

TALLMADGE, Ohio, March 11, 2025 (GLOBE NEWSWIRE) -- ProstaVive is a novel prostate support supplement that has gained popularity over the past few days. According to the team that created this supplement, it contains important nutrients clinically proven to support prostate health and achieve a stronger urine flow.

Read this article:
ProstaVive Reviews (Consumer Report Analysis) Is It Safe And Effective For Healthy Prostate Function?